Introduction
Certain transition metalsc ompounds have been demonstrated to effectively act as anticancer agents.
[1] In particular,t he inorganic complexc isplatin, cis-[Pt(NH 3 ) 2 (Cl) 2 ]( Scheme1), is currently the most widely used chemotherapeutic drug, [2] being active in the treatment of many cancers, including testicular and ovarian carcinomas, lymphoma,melanoma,and neuroblastoma. [3] The activity of this druga nd of its derivatives (carboplatin,o xaliplatin, etc.) is mediated by the formation of DNA lesions that interfere with transcription, resulting in cellular apoptosis. [1] [2] [3] In spite of their success in clinical applications, platinum compoundsa re of limited effectiveness due to severet oxicitya nd intrinsic or acquiredr esistance. Indeed, the small size and square planarg eometry of the platinum species yields only poor site discrimination at the double-helix level, with adducts forming preferentially at the most solvent-accessible guaninen ucleotides. [4] These limitations prompted the development of novel chemotherapeutics trategies aimed at exploiting the potentialo fa lternative metals, such as ruthenium. Ruthenium compounds are promising candidates, as they show selective activity against specific cancerc ell types and low toxicity. [5] The octahedralc oordination sphere of ruthenium species, in contrastt ot he square-planar geometry of platinum(II)c ompounds, imparts them with ah igherd egree of site selectivity ands ize discrimination,r esultingi nl ow toxicity and good clearance. These favorable properties have led to two ruthenium compounds-the anti-primary-tumor imidazolium trans-[tetrachloridobis (1H-indazole) ruthenate III ]( KP1019)a nd the anti-metastasis imidazolium trans-[tetrachloride (1H-imidazole) (S-dimethylsulfoxide)r uthenate III ]( NAMI-A)-that are currently undergoing clinical trials, opening new perspectives in cancer treatment. [5] Despite the increasing importance of ruthenium compounds, their cellular targets have not been unambiguously identified, andamore comprehensive understandingc ould facilitate future drug design strategies.
Although DNA has traditionally been assumed to be the primary pharmacological target of transition metal agents, recent evidencea lso indicates severalp roteins as important binding partners. [6] In particular,p roteins involved in the detoxification pathway,such as the glutathione S-transferase (GST) P1-1, have been shown to detoxify platinum compounds, such as ethacraplatin (EA-CPT). [7] Several other proteins (such as transferrin, humans erum albumin, and integrins)h ave been recognized as targets of ruthenium-based drugs.
[8] Moreover,o rganometallic ruthenium(II) agents can bind to both DNA and histonec omMany transition metal complexes have unique physicochemical properties that can be efficiently exploited in medicinal chemistry for cancert reatment. Traditionally,d ouble-stranded DNA has been assumed to be the main binding target;h owever,r ecent studies have shown that nucleosomal DNA as well as proteins can act as dominant molecular bindingp artners. This has raised new questions about the molecular determinants that governD NA versus protein binding selectivity,a nd has offered new ways to rationalize their biological activity and possible side effects. To address these questions, molecular simulations at an atomistic level of detail have been used to complement, support, and rationalize experimentald ata. Herein we review some relevant studies-focused on platinum andr uthenium compounds-to illustrate the power of state-of-the-art molecular simulationt echniques and to demonstrate how the interplay between molecular simulations and experiments can make important contributions to elucidating the target preferences of some promising transition metal anticancer agents. This contribution aims at providing relevant information that may help in the rational designo fn ovel drug-discoverys trategies.
ponents of nucleosome core particles (NCP),which are the fundamental unit of chromatin, composed of chromosomal DNA wrapped aroundahistonep rotein core.
[9] NCPs have the fundamental role of compacting DNA in eukaryotic cells, where the majority of DNA is present in ap acked conformation, rather than an aked form, such as in free oligonucleotides or non-histone protein-DNA complexes. In contrast, experimental in vitro studies and molecular simulations usually consider naked DNA to rationalize binding modes and the pharmacological action of these types of compounds.
However,t he structure of nucleosomal DNA is markedly different from that of free double-stranded DNA (dsDNA). [10] Indeed, the flexibility of naked DNA easily allows drug-induced structurala daptations, [11] whereas nucleosomal DNA is highly rigid, peculiarly benta nd restrained by the histonec omponents. In addition, the possibility of drug bindinga tt he level of the histone proteins has been shown to directly interfere with the bindingo fc hromatin transcription factors that modulate gene expression in cancer cells, [9a, b, 12] and possible epigenetic routest oa nticancert herapies have thus emerged as promising alternatives.
In recent years, simulations at the molecular and electronic structure levels have been used to complemente xperimental Dr.Giulia Palermo is apostdoctoral scientist at the EPFL in the research group of Prof. Rothlisberger,where she is working on the characterization of nucleosome dynamics and on chromatin drug design by applying classical and hybrid QM/MM methods. This research project involves close collaboration with the research groups of Prof. Dyson (bioinorganic chemistry) and Prof. Davey (X-ray crystallography). studies and providev aluable additional information.B esides identifying the binding location and binding mode of metallodrugs to dsDNA and proteins, they have also helped in rationalizing target selectivity between protein versusD NA, and assess the differences in the interaction with naked versus packed DNA. [9a, 13] High-resolution structures of nucleosomedrug adducts have recently become available, [4, 9a, 10, 14] thus paving the way for realistic molecular dynamics (MD) simulations based on classical force fields ando nq uantum mechanics (QM). In particular, QM methods are necessary for ap roper description of the electronic structure and energetics of transition metal compounds,t he intricate electronic properties of which are often not adequately described at the force-field level. However, the large size of protein-DNAt argets makes ad escription at the full QM level intractable. Ah ybrid quantum mechanics/molecular mechanics (QM/MM) approache legantly overcomes these limitations by treating the transition metal agent and its direct amino acid/nucleic acid ligands at the QM level, while the remaining part of the system,including the rest of the target biomoleculei ne xplicit solution, is described with ac lassical force field.
[15] QM/MM simulations combined with ab initio MD were able to accuratelyp redict the structural and energetic features of covalent target modifications. [16] Furthermore, ab initio QM/MM MD can be employed for generating accurate in situ force fields for target-bound transition metal compounds, which can be employedt or un long-time-scale classical MD. By using a" force-matching approach", the classical potentials are derived on the fly from QM/MM data, thus taking into account the changes in the electronic structure properties induced by the protein/nucleic acid environment as well as temperature effects.
[17]
Herein we review severalc omputational ande xperimental studies, selected from our work, aimed at characterizingt he interaction of some promisingt ransition metal anticancer agents with their biological targets.I np articular, we report how classical and QM/MMM Ds imulations have contributed to decipher the binding and reaction mechanisms of covalently bound transition metal compounds to proteins and DNA. We also show how the interplay between experiments and computations has helped in clarifyinga nd rationalizing protein versus DNA selectivity,t hus addressing relevant biological questions at the molecular level.F inally,t his article aims at providing an overview of recent computational and experimentals tudies, which have contributed to elucidating the targeting characteristics of transition metal anticancer agents. This information should facilitaten ovel drug-discovery strategies and ultimately lead to more selective anticancer agents.
Computational Methods
The computational work that we review here is based mainly on classical and hybrid QM/MM MD simulations. We introduce the basic concepts of these methods below,a nd the interested reader is referred to the reviewa rticles and books for am ore extensive description of these computational methods.
[15b-d, 18] 2.1. Force-field-based MD Force-field (FF)-based molecular simulations use the solution of the classical equations of motion for as et of particlest od escribe the time evolution of as ystem at finite temperature.
[18a]
The output is at rajectory that represents the molecular system as af unctiono ft ime. This trajectory provides insighti nto the dynamic and thermodynamic properties of the system under investigation. In classical MD, the potentiale nergy of the system is determined by an empirical FF that is parameterized to reproduce experimental or ab initio data. The FF is defined as the sum of different contributions, and is usually composed of bondedt erms, describing bond, angle bending, and torsional degrees of freedom and non-bonded terms, accounting for van der Waals and electrostatic forces. Ag eneric form of the potentiale nergy in commonly used FF for biomolecular systems is given in Equation (1):
To date, the most commonly used FFs in the simulations of biological systemsa re OPLS, [19] AMBER, [20] GROMOS, [21] and CHARMM.
[22] These FFs have been proven to excellently perform in simulations of proteins and peptides. However, severe DNA distortions and unbalanced a/g transitions were found in simulations performed with AMBER parm99F F. [20a,b] To overcome this problem, ar efinement of this FF has been developed by the group of Orozco. [20c,d] In the novel parmbsc0 FFs, ac orrect representation of the a/g transitions is provided and stable trajectories on the multi-microsecond scale can be generated.
Classical MD simulations can be coupledt om ethods enabling the enhancement of phase space sampling (i.e.,e nhanced sampling techniques), such as metadynamics, [23] accelerated MD, [24] among others, and free-energy methods such as free-energy perturbation, umbrellas ampling, adaptive biasing force, and thermodynamic integration.
[18b, 25] These methods allow the study of biophysical processes that occur on the microsecond-to-millisecond (or longer) time scale, which cannot be directly sampled in the typical time scale of (all-atom) MD simulations (i.e.,h undreds of nanoseconds to microseconds). By providing an accurate descriptiono ft he associated freeenergy landscape, these methods have been shown to be particularly efficient for the study of complex conformational changes of folded and unfoldeds tructures, [26] as well as for ligand binding. [27] 
QM/MMMD
FFs can be combined with QM methods in the so-called QM/ MM approach. Originally proposed in 1976 by Warshel and Levitt for studying the enzymatic reactioni nl ysozyme, [28] many different QM/MM implementationsh ave been proposed over the past few decades, with widespread applicationsi nb iology and materials science.
[15b-d, 29] Popular hybrid QM/MM schemes are the ONIOM [30] methodi ncludedi nt he Gaussians uite of programs, [31] or the fully Hamiltonian coupling approaches included in the CPMD [32] and CP2K codes. [33] In QM/MM studies of enzymatic catalysis and inhibition, the region of interest of the model system (the enzyme'sa ctive site and/or the ligand binding pocket) is treated at ah igherl evel of accuracy (QM level), while the remainder of the system is treated at the MM level of theory (Figure 1 ). In the general form of ah ybrid QM/ MM scheme, the total Hamiltonian (H)o ft he system contains the Hamiltonians for the quantum (H QM )a nd classical (H MM ) systemsa nd the interaction between the QM and MM regions (H QM=MM ):
where the QM Hamiltonian (H QM )c an be based on different quantum chemical electronic structure methods, spanning from semiempirical to ab initio Hartree-Focko rd ensity functional theory (DFT).I ne very QM/MM implementation, particular care must be taken to achieve ar igoroust reatment of the coupling between the QM and MM regions,a sd escribed by the interaction Hamiltonian H QM=MM .T his is especially true for the description of covalent bonds between the QM and MM regions and the treatment of the electrostatic term. To cope with the split of covalentb onds between the QM and MM regions, either linking hydrogen atoms or specially parameterized pseudo-atomsa re introduced, thus saturating the valence of the terminal QM atoms. Concerning the electrostatic interactions, the simplest way to electrostatically couple the QM and MM regions uses am echanical embedding scheme, in which the electrostatic interactions between the two regions are treated at the MM level. More rigorous is the electrostatic embedding scheme, in which the electrostatic field of the classical environment polarizes the QM electronic charged ensity and the interaction between MM point charges and QM electron density is incorporatedi nH QM .I nathird polarized embedding scheme, the polarization effects of the QM region on the MM part are also considered self-consistentlyi nt he frameworko f ap olarizable FF.T he remaining bonding and van der Waals interactions between QM and MM regions are treatedc lassically.
Since their first appearance, [28] QM/MM approaches have been successfully applied to ag rowing number of drugdesign-related studies and to elucidate enzymatic mechanisms.
[15b, c, 16a, 27b, 34] Moreover,c ontinuous developments in the field have enabled studies of the reaction mechanismso fb iological systems of increasing size (up to 200 000 atoms) and complexity. [35] Notably,t he 2013 Nobel Prize in Chemistry was given in recognition of the seminalc ontributionso fK arplus, Levitt, and Warshel in developing multiscale modelsf or complex chemical systems. The QM/MM scheme was specifically mentioned in honoring the groundbreaking work of the Nobel laureates in the field of molecular simulations.T he QM/MM method,i nc ombination with first-principles (Car-Parrinello) MD, is widely employed for the study of anticancer drugtarget interactions. [11, 15] Herein we review applications of the fully Hamiltonian QM/MM extension to Car-Parrinello MD developed by Rothlisberger and co-workers. [36] In this approach, the electrostatic effects of the classicale nvironmenta re taken into account via an electrostatic embeddings cheme in the form of an additional contributiont ot he external potential acting on the QM system. The Pauli repulsion between the electrons and the classical point charges is mimickedt hrough the use of as creened Coulombp otential in order to avoid over-polarization of the electron density near positively chargedc lassicalp oint charges (i.e.,t he so-called electronic spill-out effect). ThisQ M/MM approach is implemented in the Car-Parrinello code (CPMD) [32] based on DFT in combination with the classical AMBER [20] andG ROMOS [37] FFs using particle mesh Ewald summation to treat long-range electrostatic interactions.
The QM (Car-Parrinello)/MM methodc an be used in combination with the "force-matching approach" for generating reliable in situ force fields for nonstandard residues,s uch as amino/nucleic acids boundt ot ransition metal complexes. In the methodd eveloped by Maurer et al., [17] the QM region is chosen in such aw ay to include all components of the system for which no parameters are available. Finite-temperature QM (Car-Parrinello)/MM MD simulations are used to generateatrajectory of reference configurations. Next, the nuclear forces acting on the atoms of the QM subsystem are extracted from the obtained trajectory and stored. As et of optimal atomic point charges that reproduces the electrostatic potential and field in the surroundingo ft he QM region is determined, taking into account all trajectory configurations. The stored forces serve as targets for the subsequentp arameter-fitting scheme. Indeed, the force-field parameters are determined in such aw ay as to optimally reproduce the electrostatic properties and the nuclear forces of the QM subsystem. The optimized FF parameters obtained can be used to perform molecular simulationsw ith the accuracyo faQM/MMt reatment at the computational cost of classical MD. The action of cisplatin and related platinum compounds is greatly limited by the occurrence of drug resistance, which has been associated, among other factors such as the recognition of platinated DNA by repair proteins, [38] to an overexpression of the p-class glutathione S-transferase (GST P1-1) enzymei n cancer cells. [3] GST P1-1 is ad etoxification enzyme within the mercapturic acidp athway that catalyzes the conjugation of xenobiotics to glutathione, thus leadingt ot he elimination of toxic compounds.R ecently,anovel Pt IV compound, termed ethacraplatin (EA-CPT, Scheme 1), has been reported to exert anticancer activity and simultaneouslyi nhibit GST P1-1, thus overcoming the associated drug resistance. EA-CPT has the ability to be reduced intracellularly to release ac ytotoxic Pt II moiety and two ethacrynate (EA) molecules, whicha re directly responsible for GST P1-1 inhibition.
To understand the nature of the drug-protein interaction, ad etailede xperimental and theoretical study has been conducted. [7] X-ray crystallography captured the configuration of Pt II after its release from the EA-CPT molecule and the binding of the EA fragments (Figure2a). In the crystal structure, Pt II is coordinated by two cysteiner esidues (C101/C101')a nd by achloride ion at the protein dimer interface, while the released EA fragments locate within two accessible hydrophobic pockets. QM/MM simulations have been used to establish the nature of the remaining exogenous ligand coordinated to the Pt II center,w hich could not be discerned from the electron density map in the X-ray structure. As ar esult,afourth Pt II ligand-most likely ah ydroxy group-is required for ensuring the stabilityo ft he active site during QM/MM MD. Subsequently,m olecular simulations have been used to investigate how the binding between the intact EA-CPT and GST P1-1 takes place. ClassicalM Ds imulations were carriedo ut in combination with metadynamics, [23] which allowed ad ynamic docking of EA-CPT from the bulk to the target active site, efficiently exploring different binding poses and constructing the associated free-energy profile. These simulationse nabled discrimination among various binding routes, revealing that EA-CPTp referentially approaches the cysteine residues at the protein dimer interface (Figure 2b) .
This binding mode is in agreement with previous structural studies of the EA ligand in complex with GST P1-1. [39] Overall, the work suggested that EA-CPT first migrates to the GST P1-1 dimer interface, where it is subsequently reduced and cleaved, permitting the diffusion of both ac ytotoxic Pt II species ando ft he EA fragments, whichl ocate within the hydrophobic enzymec avities. Accordingt ot his mechanism,t he Pt IV ion of EA-CPTi sr educed upon binding at the dimer interface to Pt II ,t he two ethacrynate ligandsa re released and inhibit GST P1-1, thusa llowing the Pt II speciest oe xert its cytotoxic action withoutbeing inactivated by GST-mediated resistance.
Ruthenium Compounds

Active species of Ru III -basedd rugs
AmongR u-baseda nticancer drugs,p romising candidates are NAMI-Aa nd KP1019 (Scheme 1). [5] Both compounds are octahedral,b earing four chlorides and differing in the axial ligand. NAMI-Ah as been evaluated in several in vivo modelsa nd has been shown to prevent the developmenta nd growth of pulmonarym etastases in all the solid tumors on which it has been tested in vivo, including Lewis lung carcinoma, [40] MCa mammary carcinoma, [41] TS/A mammary adenocarcinoma, [42] and human tumors in mice. [43] KP1019, on the other hand, significantly decreases tumor growth in severali nv ivo models, including chemoresistant tumors, such as colorectalc ancer. Both NAMI-A and KP1019 have already completed phaseI and II clinical trials. [5] Despite their structurals imilarity,N AMI-Aa nd KP1019,a sw ell as the imidazole analogue of the latter (KP418), have completely different biological effects, principally due to their different targeting abilities. NAMI-A weeklyb inds to DNA, [44] whereas it strongly binds to severalp roteins (integrins, transferrin, human serum albumin, human carbonic anhydrase,a nd lysozyme).
[8] In contrast, KP418r eacts with DNA, inhibitingD NA synthesis. [45] Because NAMI-A can prevent metastasis in part by the inhibition of angiogenesis in several experimentalm odels, it is believed that its mechanism of action might include modulation of various protein targets, such as proteases,p rotein kinases,a nd integrins, all known to play key roles in cell motility and invasion.
[8] However,i ti sn ot fully clear which biological targets are responsible for its activity. This lack of knowledge has hampered af ull mechanistic understanding of the mode of action of NAMI-A. Like cisplatin, Ru compounds are administered as prodrugs and predominantly remain in their less reactive chloride form at high chloride concentration,such as in blood plasma. At low chloride concentration, as in the cellular environment, they rapidlyundergo aqua- Figure 2 . a) Crystal structureo fG ST P1-1, including the ethacrynic acid (EA) moieties and the Pt II ion. [7] GST P1-1 is represented as am olecular surface, highlighting the two protein dimers with gray and pink ribbons.The EA moiety( violet) is shownins pace-filling representation, while the Pt ion is shown as agreen sphere.C 101/C101' are also shown as sticks. b) Binding mode of the intact EA-CPT approaching the GST P1-1 dimer interface from classical and QM/MMsimulations. The ligand exchange reaction activates the Ru agent,a st he aqua ligandsc an rapidly be replaced by the electron-donor ligands of biomolecules (i.e.,p roteins and DNA). Thus, understanding the exchange kinetics in solution is of paramount importancet oi dentify the active metabolites and the ease by which they are formed.
Theoretical studies have focusedo nt he study of the kinetics of ligand-watere xchange of NAMI-Aa nd KP418, such as rationalizing the differences between the most abundantm etabolites formed in solution.A ne xtensive studyb ased on DFT-B3LYP calculations in implicit solventh as been performed on NAMI-Aa nd KP418 complexes considering both Ru II and Ru III oxidation states. [46] The two compounds exhibit remarkably different redox potentials (E m ,v ersus normalh ydrogen electrode NHE), which are 0.235 and À0.275 Vf or NAMI-A and KP418, respectively (Table 1) . Because of its E m ,N AMI-Ac an be easily reduced in vivo by biological reductants, while this process may be more difficult for KP418.
Considering that the reduction of NAMI-Ar apidlyo ccurs in vivo, as mediated by biological reductants, it is likelyt hat the most abundant species in solution would be the Ru II -monoaqua or cis-o rtrans-Ru II -diaqua metabolites (Scheme 2). In contrast, in the absence of reductants, the Ru III compound would immediately dissociate DMSO and retain the Ru III oxidation state as observed in X-ray studies (Figure 3) .
[8g] The X-ray structure of the adduct between NAMI-A in its Ru III form and carbonic anhydrase indicates that NAMI-A behaves like am ultistage drug, progressively releasing all ligands, and with the Ru center binding to the final protein target residues (Figure 3 ). Thus, depending on the bioavailability of reductants, am ixture of cis-a nd trans-Ru II -diaquaN AMI-A metabolites may be active, or the DMSO ligand might be immediatelyl ost, activating Ru III for the protein target.
The reduction of KP104 is more difficult and if it occurs, it has no effect on the hydrolytic properties of the molecule. [46] In this case the most active speciesa ppears to be the cis-Ru IIdiaqua isomer (Scheme 2). The reduction of KP418 most likely occurs after the second hydrolysis step, because the E m values increasea sh ydrolysisp roceeds (Table 1) . Thus, for KP104, the most active metabolite likely maintains the chemical differences of the parent compound, as the imidazole ligands are still present in the cis-diaquo-Ru III metabolite (Scheme 2). Ta ken together,t hese different kinetic properties appear to affect the biodistribution of the two drugs and in turn their binding preferences to biological targets.
Ru
II -arene (RA) compounds and DNA targeting Ru II -arene (RA) compounds have emergeda sp romising alternatives to platinum compounds. [47] The prototypes are [Ru NAMI-A KP418 Calcd. [b] Exptl.
Calcd. [b] Exptl. (RAED) [48] and [Ru II (h 6 -arene)Cl 2 (1,3,5-triaza-7-phosphoadamantane)] (RAPTA) [49] (Scheme 1). These "piano stool" complexes are characterized by a p-bonded arene ligand as the "seat of the stool", with am onodentate phosphine 1,3,5-triaza-7-phosphadamantane (PTA) or ac helating ethylenediamine( ED),a nd chloride ligands occupying the remaining coordination sites. The arene ligand providesahydrophobic surface that fosters ah ighd egree of selectivity toward biomolecular targets. [50] As for Ru III -based drugs, the ligand exchange kineticsc an be exploited to modulate the rate of reactiono fR Ac ompoundsw ith biomolecular targets,b ys ubstituting other (labile) ligandsi np lace of the chlorides. [50, 51] The versatility of RA compounds prompted the development of related compounds, leadingt oavast number of compounds that have been evaluated for cytotoxicity in cancer cells. Buildingo nt he knowledge of the main molecular target of cisplatin-i.e.,d sDNA-it has been suggested that RA compounds target guanine bases at the mostreadily accessible electron donora tom (N7). [52] However, an early (rigid) docking study for an organometallic complex,[ Cp 2 Mo] 2 + ,i ndicated that transition metal-arene compounds are too bulky to bind to the DNA major groove in am anner analogous to that of cisplatin. [53] To investigate the binding processes of the monofunctional RAED-Ca nd of the bifunctionalR APTA-C compounds to dsDNA,c lassical and ab initio QM/MM MD simulations have been performed.
[13b] These simulations considered as ad rug target am odel sequence of dsDNA containing two guanine bases in the central part of a1 2-mer dsDNA, as previously used in studies of cisplatin binding. [54] The initial approacho f RAED-Ct od sDNA has been investigated by placing the [Ru(h 6 -p-cymene)(ED)] 2 + moiety at a~20 d istance from the target guanine( i.e.,G 6, Figure 4a ), considering different starting conditions facing both the minor and major DNA grooves. Unconstrained classical MD showed that RAED-C is easily accommodated within the major groove of the dsDNA on a~15 ns time scale, exhibiting strong selectivity for GC-richs equences.I n these classical MD studies, the Ru II ions amples configuration distances as close as 4 from one of the DNA binding atoms (i.e.,N 7@G6) reachinga lmostb inding distances. Moreover,t he amino group of the ED moiety forms ac haracteristic hydrogen bond with O6@G6, in agreement with previouss tudies. [55] MD simulations show that the high flexibility of dsDNA decreases the steric hindrance of the bulky p-cymene group, allowing RAED to fit easily within the major groove, allowing covalent binding at G6. Startingf rom these configurations, the formation of the coordination bond betweenR AED-Ca nd N7@G6 has been studied by QM/MM MD in combination with the thermodynamic integrationa pproach, which allows calculating the free energy of ap rocess along as elected reaction coordinate.
[18b] By using this approach, ad issociativem echanism of water/N7@G6e xchange characterized by af ree-energy barrier of~11 kcal mol À1 for the formation of the covalent RAED-C-DNA complexw as observed. For the dissociation of RAED-C from DNA, af ree-energy barrier of~21 kcal mol À1 was calculated. The binding of RAPTA-C to dsDNA has been suggestedt o occur in as imilar way.I ndeed, by calculating the electrostatic potential( ESP) of the [Ru(h 6 -p-cymene)(PTA)]
2 + moiety and of the target dsDNA, it was shown that the binding at the major groove level should be driven mainly by electrostatic interactions ( Figure 4b ). As indicated by these calculations, the highly negative ESP of the dsDNA major groove allows the formation of as uitable binding cavity for the positively charged RA compounds.
To gain insight into the long-time-scale DNA distortions induced by the covalent binding of RA compounds to dsDNA oligonucleotides, classical MD simulations of the RA compounds-DNA adducts were carried out, by employing aQ M/ MM MD tuned (force-matched) FF.D uring nanosecond-long classical MD simulations, RAED-C and RAPTA-C induced ifferent structurald istortions to dsDNA. Namely,R AED-Cb inding causes al arge increase in the rise between T5 and G6 bases, such that the typical Watson-Crick base pairing between T5 and A20 is broken (Figure 4c ). This results in as ubstantial openingo ft he major groove andp artial DNA unwinding, in agreement with previous experiments,s uggesting the formation of al ocal single-stranded DNA. [56] On the other hand, the binding of RAPTA-C introduces ag lobal overall bending of the www.chemmedchem.org DNA (~408)t owardt he major groove. This structural distortion is similart ot he DNA bent configuration induced by the widely used anticancer drug cisplatin, which is believed to play ac rucial role in its mechanism of anticancer activity. [57] Overall, molecular simulations have shown that even bulky RA compounds can bind to DNA due to the high flexibility of the double strand,w hicha llows rapid accommodation of the compounds within its wide major groove. However,u pon covalent binding at the target guanine, RAED-C and RAPTA-C induce different local and global perturbations to the naked dsDNA oligonucleotides tructure.
RA compounds and nucleosome targeting
It was recently demonstrated that RA compounds bind directly to NCPs, [9a, b] which are the fundamental unit of chromatin and are composed of chromosomal DNA of 145-147b ase pairs (bp), wrappeda rounda no ctamer of four core histoneproteins (H3, H4, H2A and H2B, Figure5a). The packaging of the genome into nucleosomes raises the possibility to form either potentiala dducts at differentD NA sites, or to form protein adducts at exposed sites of the histone core. [58] The latter are particularly interesting, because histone binding may directly influence gene expression, opening new avenues for possible epigenetic cancer therapies. [9b, 12] At the nucleosome level, the binding of RA compounds is very different from that of cisplatin and other cytotoxic platinum-based agents, which bind to many different DNA sites within the NCP. [4, 14, 59] By using quantitative bioanalytical methods, it has been shown that the chromatin-bound adductsi n cancer cells treated with RAPTA-C are primarilya ssociatedw ith the protein components,w hileR AED preferentially targets the DNA components of chromatin.
[9a] X-ray crystallography revealed three well-definedh istoneb inding sites for RAPTA-C (Figure 5a ), whereas RAED-Cf orms adducts preferentially at the DNA sites with only one additional binding site at the histone level. RAED-C binds at guanine sites of the nucleosomal DNA, in analogy with its binding mode to nakedD NA, [56, 60] however,w ith av astly different site selectivity,a sm ost of the reactive sites on naked DNA are not accessible in the NCP due to the histone packaging. Indeed, the only accessible sites for adduct formation are at the termini and at locations 1.2 and 2.5 double-helical turns away from the NCP center [also called superhelix location (SHL) AE 1.5 and SHL AE 2.5].R emarkably, both RAPTA-C and RAED-C preferentially bind to glutamate sites of the histonec omponents, while displaying very different histone (RAPTA-C) versus DNA (RAED-C) specificities.
To understand the molecular basis of this site selectivity, QM/MMs imulations of the adduct formation of RAPTA-C and RAED-C were performed at selected histone and DNA sites (Figure 5b ). Whereas the two compounds presentasimilar free-energy barrier (~20 kcal mol À1 )t ob ind to the histone sites, the barrier for adduct formation at the DNA sites is twofold higher for RAPTA-C (~30 kcal mol
À1
)t han for RAED-C (1 5 kcal mol
). This difference in free energy at the DNA level is due to the steric constraints of the nucleosomal double helix, which hampers the accommodation of the larger PTAl igand duringa dduct formation. As ac onsequence,t he activation free-energy barrierf or RAPTA-C binding to DNA considerably increases whilea dduct stability is significantly decreased so that the binding of RAPTA-C to DNA is both kinetically and thermodynamically unfavorable (Figure 5b) . Instead, the steric hindrance of the PTAl igand favors the accommodation of RAPTA-C at the histone sites via shape and hydrophobic complementarity.T his evidencep oints to the steric difference between the PTAa nd ED ligands as the main factor underlying histonev ersus DNA site preference. This also suggestst hat the much higher cytotoxicity of RAED-C may be related to its lesion-forming proclivity,w hereas the propensity of RAPTA-C to form protein adducts mayb ea tt he origin of its distinctly different therapeutic action. [9a] 
RAPTAc ompoundsand chromatin compaction
The bindingo fR APTA-C occursa tt he so-called NCP acidic patch,w hich is ap rominently negatively charged region of the histonec omponents, located at the H2A/H2B interface ( Figure 6 ) and composed by eight negatively charged residues (E56, E61, E64, D90, E91, E92, E102, E110).
[9] Amongt hese residues, E61a nd E64 coordinate the Ru II centero fRAPTA-C in Figure 5 . a) Nucleosomal adducts of RAED-C (left panel) and RAPTA-C (right panel). [9a] Histonep roteins are showni nb lue (H3), green (H4),y ellow (H2A), and red (H2B)ribbons, while the two 145-nucleotideDNA strands are shown as cyan and violetsticks.R AED-Ca nd RAPTA-C are shown in space-filling representation. RAED-C preferentially associates to the nucleosomalDNA (Sites SHL À1.5/ + 1.5), while also binding at the histonecomponents (Sites 2a nd 4/4'). RAPTA-C selectively formsa dductsa tt he protein histones (Sites 1-3). b) Free-energyp rofiles for adduct formation by RAED-C and RAPTA-C at histone glutamate (Site 2, left panel) or DNA guanine (Sites SHL À1.5/ + 1.5, right panel), as obtained from QM/MMs imulations via the thermodynamic integrationa pproach (i.e.,byi ntegratingthe constraintforce along the selected reaction coordinate, which is reported on the x-axes of the graphs). Selecteds napshots of the nucleosomal adducts are also reported. RA compounds and the NCP reactive residues (DNA guaninea nd histone glutamate), which were treateda tthe DFT(BLYP)/QM level,a re shown in CPK representation. Adaptedf rom Ref. [9a] .
Site 2, while E102 in conjunction with H106 coordinates RAPTA-C in Site 3.
The NCP acidic patch is acharacteristichot-spot for the binding of chromatin factors, which are enzymes that alter the degree of chromatin compaction by specific interactions at the NCP level. Chromatin factors are therefore crucially involved in regulating histonep ost-translationalm odificationsa nd directly controlg ene expression. [12] The crystal structures of chromatin factors bound to the NCP are characterized by ac ommon arginine interaction motif that binds the NCP acidic patch.R APTACs ubstitutes the arginine interaction motif of chromatin factors, by the positively charged Ru II ion engaging ligand coordination with the glutamate residues of the NCP acidic patch. This suggeststhat RAPTA-C interferes directly with the modulation mechanisms of chromatin compaction and with the histone post-translationalmodifications. Figure 6b -d shows the superpositions of the crystal complex of the NCP and RAPTA-C with the structureso ft he RCC1 (PDB ID:3 MVD), [61] Sir3 (PDB ID:3 TU4), [62] and PRC1 (PDB ID: 4R8P) [63] chromatin factors bound to the NCP.An et overlap of RAPTA-C with the arginineinteraction motif of these chromatin factors is observed, indicating that RAPTA-C binding directly interferesw ith chromatin-factor-mediated regulation. In detail, the b-propeller protein RCC1 (regulatoro fc hromatin condensation, Figure 6b )i sag uanine exchange factor for the Ran GTPasep rotein, which is critical in regulating important eukaryotic cellular functions, such as nuclear transport and mitosis. [61] RCC1 binds to the histone core of the NCP using R223, which interacts with the E61, D90, and E92 residues of the NCP acidic patch.A nalogously to RCC1, the bacterial Sir3 (silenti nformation regulator,F igure 6c)p rotein, which establishes transcriptionally repressive chromatin states, binds to the NCP acidic patch by using Arg29 as an anchor. [62] The argininei nteraction motif is also observed in the PRC1 (polycomb repressive complex, Figure 6d )p rotein, which ubiquitylatest he nucleosomal histone H2A K119 residue, acting as at ranscriptional repressorw ith ac rucial role in severalh uman cancers. [63] PRC1 extends R98 into the NCP acidic cavity,i nteracting with the E61, D90, andE 92 residues.
The crystallographic studies indicatet he direct interference of RAPTA-C with the mechanismso fc hromatin compaction and histone post-translational modifications. Thus, the binding of RAPTAc ompounds at the histonel evel impacts the epigenetic mechanisms at the molecular level and exerts ad irect action on gene expression.
Conclusions
Hereinw er eview severali nformatives tudies that have critically contributed to elucidating key aspects of the targeting characteristics of promising organometallica nticancer agents. These studies provide insight into the main factors that may be responsible for modulating the binding preferences of these compounds toward DNA and protein targets.
We show that subtle changes of the ligand spheres may strongly affect the redox potentialo ft he drugs with direct impact on the nature of the most likely metabolite species available, and consequently on the biodistribution andb iological activity of the compounds. We also report how the ligand exchange mechanism, which can be modulated by changing the number of chloride ligands that are exchanged by water duringt he formation of the active drugs, affects the binding mechanism at the target level. We showcase the remarkably different characteristics of drug-DNAi nteractions for naked Figure 6 . a) Electrostatic propertieso ft he histone protein core, highlighting the NCP acidic patch,anegatively charged region located at the grooveinterfaceo ft he H2A and H2B histones. The ESP was calculated and mapped onto the protein solvent-accessible surfaces [red = negative (À5kTe À1 ); blue = positive(+ 5kTe À1 )] of apo NCP (PDB ID:1AOI).
[9c] Ac lose-up view of the NCP acidic patch is shown at right, showing eightnegatively charged residues (E56,E61,E64,D90,E91, E92,E102, E110) as sticks. Asterisks indicate the E61,E 64, and E102 residues that are engaged in ligand coordination with RAPTA-C in the adduct X-rays tructure.
[9b] b)-d) Superpositionso ft he crystala dduct of the NCP with RAPTA-C [9b] with the structures of the b) RCC1 (PDB ID:3MVD), [61] c) Sir3 (PDB ID:3 TU43TU4), [62] and d) PRC1 (PDB ID:4R8P) [63] chromatin factorsbound to the NCP.R APTA-C is showntooverlap with the arginine interaction motif of chromatin factors, directlyi nterfering with their molecular mechanism of nucleosome binding. For each system,aclose-upv iew of the arginine interaction motif is provided, highlightingthe interaction of aconserved argininew ith the NCP E61, D90, and E92 residues.C hromatin factors (blue)a re showna sr ibbons. RAPTA-C is shown in space-filling representation,a sw ell as the conserveda rginine residue of chromatin factors. For clarity,R APTA-C bounda tS ite 1i so mitted.
ChemMedChem 2016, 11,1 199 -1210 www.chemmedchem.org and packed DNA. Whereas the former is ah ighly adaptable and flexible target, the latter acts as as terically highly selective construct. Steric effects due to bulky ligands also appear as the essential molecular discriminators for histonev ersus DNA binding. This selectivity can markedlya ffect the antitumor/antimetastaticproperties of Ru-based drugs.
As af urtherr emark, we show that drug binding at the level of histone proteins directly interferes with the molecular mechanismso fc hromatin compaction and gene expression in cancer cells. This is ac rucial point, considering that the selective targetingo ft he histonec omponents can interferew ith the epigenetic mechanismsa tt he molecular level, thus paving the way for novel drug-discovery strategies. Overall this review shows how the synergismbetweenexperimentsand molecular simulations may contribute to an in-depthc omprehension of the mechanism of action of metal-based drugs,e lucidating mechanistic detailsa ta na tomistic level, which are often inaccessibletoexperiments and molecular simulationst aken singularly.
